AstraZeneca is banking on sustained **oncology demand** through 2026, but this isn't just about drugs; it's about market control and the future of **pharma technology** investment.
VCU Health's purchase of Hope Pharmacy isn't about better service; it's a calculated move in the fierce **academic medical center** consolidation war. Unpacking the real winners.
Forget the headlines. The real drivers of skyrocketing US healthcare costs aren't just Big Pharma—they're the silent epidemics fueled by nutritional ignorance, a topic journalists are finally dissecting.
Dr. Dennis Slamon's honor in precision medicine masks the crushing reality of high drug costs and access inequality in modern healthcare.
The new Medicare drug price negotiation list isn't about saving seniors money; it’s a calculated political strike against Big Pharma.
The recent Health Solutions Summit focused on fiscal restraint, but ignored the hidden costs of US healthcare reform.
The recent House Appropriations minibus signals an uneasy truce, but the real winners in this 'key health programs' funding package aren't who you think.
The new map of biomedical translational science isn't about progress; it's about control. Discover who's truly winning in the science-to-market race.
Trump's supposed healthcare fix ignores the core issue, ensuring ACA premium hikes continue for millions.
Life science executives learned a painful lesson from political whiplash. It’s not about ideology; it's about predictable regulatory capture.
Forget swing voters. The real battleground for the 2026 elections isn't the economy—it's the crushing reality of healthcare costs and prescription drug access.
GLP-1s are bankrupting health insurers faster than predicted. This isn't just about weight loss; it's a systemic failure.